Revision as of 09:14, 26 September 2012 by UrbanB (Talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


We have considered as examples for the proof of principle two different diseases that could be treated by the use of our synthetic microencapsulated cellular device (Figure 1):

  • The therapy of hepatitis C by the local production of interferon alpha followed by the production of hepatocyte growth factor, providing a regeneration step.
  • The therapy of ischaemic heart disease with anakinra as an antiinflammatory agent, while vascular endothelial growth factor and platelet-derived growth factor, produced in stoichiometric amounts enhance angiogenesis and tissue oxigenation.

Next: Hepatitis C >>